BDX BCAL Diagnostics Limited
—Mkt Cap: —P/E: —1d ago
BCAL Diagnostics Limited, a biotechnology company, engages in developing a novel blood screening test to support the early diagnosis and monitoring of breast cancer in Australia. It is involved in the development and com…
Industry Peers
Biotechnology$128.87BUSDP/E 29.6
$94.42BUSD
$81.99BUSDP/E 19.1
$53.47BUSDP/E 32.5
$53.22BUSDP/E 31.6
$44.02BUSDP/E 17.8
$42.56BUSDP/E 66.4
$40.57BUSD
$34.45BUSDP/E 30.4
$31.32BUSDP/E 39.3
$24.59BUSD
$23.32BUSDP/E 31.7
$23.26BUSDP/E 29.8
$22.96BUSDP/E 14.0
$22.66BUSD
$21.67BUSD
$15.57BUSDP/E 19.3
$14.91BUSDP/E 17.4
$13.92BUSDP/E 14.7
$13.79BUSDP/E 33.4
Key Statistics
Company
Market Cap—
Enterprise Value23.81M USD
Revenue (TTM)1.63M USD
Gross Profit14.95K USD
Net Income (TTM)-5.00M USD
Revenue/Share0.0060 AUD
Last Price—
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees—
CountryAU
SectorHealthcare
IndustryBiotechnology
ISINAU0000160921
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-5.23
EV/Revenue14.65
P/S12.38
P/B-39.50
EPS (TTM)-0.02
EPS (Forward)—
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin100.00%
Oper. Margin-313.41%
EBITDA Margin-280.17%
Profit Margin-33465.98%
ROE-116.40%
ROA-73.08%
Growth
Revenue Growth-14.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-4.26M USD
CapEx (TTM)544.35K USD
FCF Margin-168.40%
FCF Yield—
Net Debt3.68M USD
Net Debt/EBITDA-0.81
Balance Sheet
Debt/Equity0.38
Current Ratio1.36
Quick Ratio1.32
Book Value/Sh-0.0020 AUD
Cash/Share0.0040 AUD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 AUD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.368.68M
Float175.35M
Insiders50.77%
Institutions2.65%
Technical
SMA 500.0730 AUD
SMA 2000.0876 AUD
Beta0.74
S&P 52W Chg16.44%
Avg Vol (30d)—
Avg Vol (10d)211.78K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—